TGNA
72
5
SYK
46
4
R
57
-3
PNR
47
2
SIG
54
2
EMR
56
-4
BF.B
54
-4
WDC
40
2
WEC
82
2
DNB
64
4
PFE
33
3
CAT
46
-2
PNW
71
-2
LB
60
-4
STI
20
2
VTR
58
-2
MCHP
43
-3
CVX
61
3
KMI
77
-4
EQIX
45
-2
TGNA
72
5
SYK
46
4
R
57
-3
PNR
47
2
SIG
54
2
EMR
56
-4
BF.B
54
-4
WDC
40
2
WEC
82
2
DNB
64
4
PFE
33
3
CAT
46
-2
PNW
71
-2
LB
60
-4
STI
20
2
VTR
58
-2
MCHP
43
-3
CVX
61
3
KMI
77
-4
EQIX
45
-2
Financhill
Back

Range Cancer Therapeutics ETF Stock Predictions

The Tariff-Proof Asset in Your Pocket

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
15

CNCR
Range Cancer Therapeutics ETF

Last Price:
$11.14
Seasonality Move:
-1.76%

7 Day Trial

ALL ACCESS PASS

$ 7

Economy going through a "period of transition" - Your portfolio doesn't have to

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.

Range Cancer Therapeutics ETF Stock Forecast

  • Over the next 52 weeks, Range Cancer Therapeutics ETF has on average historically fallen by 0.5% based on the past 9 years of stock performance.
  • Range Cancer Therapeutics ETF has fallen lower in 5 of those 9 years over the subsequent 52-week period, corresponding to a historical accuracy of 55.56%
  • Is Range Cancer Therapeutics ETF Stock Undervalued?
    The current Range Cancer Therapeutics ETF [CNCR] share price is $10.53. The Score for CNCR is 15, which is 70% below its historic median score of 50, and infers higher risk than normal.
  • CNCR is currently trading in the 10-20% percentile range relative to its historical Stock Score levels.

Will Range Cancer Therapeutics ETF Stock Go Up Next Year?

  • Over the next 52 weeks, Range Cancer Therapeutics ETF has on average historically fallen by 0.5% based on the past 9 years of stock performance.

Range Cancer Therapeutics ETF Stock Rating

Sell
15
Range Cancer Therapeutics ETF (CNCR) is a Sell

Is Range Cancer Therapeutics ETF overpriced?

  • Range Cancer Therapeutics ETF has fallen lower in 5 of those 9 years over the subsequent 52-week period, corresponding to a historical accuracy of 55.56%

Range Cancer Therapeutics ETF Stock Price History

Is CNCR stock going to rise?

  • Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and CNCR is experiencing selling pressure, which indicates risk of future bearish movement.

Stock Information

Stock Info

Exchange:
NASDAQ
Country:
Industry:
Sector:
Type:
etf
Website:

52-Week Data

52-Week High:
16.78
52-Week Low:
10.44

Prediction Charts

Market Cap:
0
Price in USD:
10.53
Volume:
1.7K
Beta:
1.12

Technical Analysis

SMA50:
11.93
SMA100:
12.99
SMA200:
13.80
52-Wk Change:
-34.15%

Stock Predictions

  • Is Range Cancer Therapeutics ETF stock public?
    Yes, Range Cancer Therapeutics ETF is a publicly traded company.
  • What is the Range Cancer Therapeutics ETF stock quote today?
    The Range Cancer Therapeutics ETF stock price is 10.53 USD today.
  • How to buy Range Cancer Therapeutics ETF stock online?
    You can buy Range Cancer Therapeutics ETF shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date Opening Closing Minimum Maximum
Feb-26 11.76 11.62 11.82 11.56
Feb-27 11.65 11.27 11.74 11.26
Feb-28 11.21 11.38 11.38 11.10
Mar-3 11.48 10.85 11.48 10.81
Mar-4 10.60 10.79 10.84 10.56
Mar-5 10.83 11.09 11.09 10.83
Mar-6 10.88 11.06 11.09 10.88
Mar-7 11.08 11.10 11.10 11.08
Mar-11 10.64 10.83 10.83 10.44
Mar-12 10.92 10.93 10.97 10.87
Mar-13 10.85 10.65 10.85 10.65
Mar-14 10.71 10.71 10.71 10.71
Mar-17 10.66 10.83 10.83 10.66
Mar-18 10.55 10.53 10.62 10.53

Range Cancer Therapeutics ETF Earnings

Data Unavailable

Range Cancer Therapeutics ETF Forecast Revenue Growth

Data Unavailable

* Range Cancer Therapeutics ETF stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.